Agnieszka Kurek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agnieszka Kurek has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Lejman
10th Military Clinical Hospital with Independent Public Healthcare Centre Polyclinic in Bydgoszcz, Bydgoszcz, Poland
10 shared publications - Aleksandra Mazurkiewicz
1st Military Clinical Hospital with Outpatient Clinic in Lublin, Lublin, Poland
10 shared publications - Hubert Sidor
Military Institute of Medicine in Warsaw, Mazovia, Poland
10 shared publications - Monika Wołosik
Military Institute of Medicine in Warsaw, Mazovia, Poland
10 shared publications - Natalia Bednarczyk
10th Military Clinical Hospital with Independent Public Healthcare Centre Polyclinic in Bydgoszcz, Bydgoszcz, Poland
10 shared publications - Natalia Krajewska
Military Institute of Aviation Medicine in Warsaw, Mazovia, Poland
10 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
ADVERSE EFFECTS OF ESKETAMINE IN TREATMENT RESISTANT DEPRESSION: A COMPREHENSIVE LITERATURE REVIEW (2020-2025)
Background: Esketamine nasal spray represents the first FDA approved treatment with a novel mechanism of action for treatment resistant depression (TRD) in decades. While its efficacy has been well established, a thorough understanding of the adverse effect profile remains essential for informed clinical decision making and optimal patient safety. We therefore undertook this systematic review to characterize the safety profile of esketamine in treatment resistant depression. Aim: This review examines esketamine's adverse effect profile, focusing on common effects, cardiovascular safety, urological considerations, cognitive outcomes, abuse liability, special populations, and serious adverse events. Materials and Methods: We performed a comprehensive literature search across multiple databases including PubMed, Cochrane Library, Web of Science, Embase, Google Scholar, and MEDLINE for studies published 2020-2025. Results: Common adverse effects like dissociation and sedation resolved within two hours. Blood pressure elevations normalized within 1.5 hours without intervention. Pre approval concerns were not confirmed: no bladder cystitis occurred despite years of exposure, cognitive function remained stable or improved, and misuse was rare (less than 0.01%). Serious adverse events were infrequent (less than 0.2% of sessions), occurring mainly during initial treatments. Mortality rates matched background rates in treatment resistant depression. Elderly patients showed similar tolerability but needed closer cardiovascular monitoring. Conclusion: Under proper clinical supervision, esketamine shows an acceptable safety profile. Most adverse effects are temporary and mild to moderate. Long term studies extending up to 6.5 years found no evidence of organ damage, cognitive decline, or meaningful abuse problems. For patients who have failed multiple treatments, esketamine provides an important alternative with manageable safety concerns.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessADVERSE EFFECTS OF ESKETAMINE IN TREATMENT RESISTANT DEPRESSION: A COMPREHENSIVE LITERATURE REVIEW (2020-2025)
Background: Esketamine nasal spray represents the first FDA approved treatment with a novel mechanism of action for treatment resistant depression (TRD) in decades. While its efficacy has been well established, a thorough understanding of the adverse effect profile remains essential for informed clinical decision making and optimal patient safety. We therefore undertook this systematic review to characterize the safety profile of esketamine in treatment resistant depression. Aim: This review examines esketamine's adverse effect profile, focusing on common effects, cardiovascular safety, urological considerations, cognitive outcomes, abuse liability, special populations, and serious adverse events. Materials and Methods: We performed a comprehensive literature search across multiple databases including PubMed, Cochrane Library, Web of Science, Embase, Google Scholar, and MEDLINE for studies published 2020-2025. Results: Common adverse effects like dissociation and sedation resolved within two hours. Blood pressure elevations normalized within 1.5 hours without intervention. Pre approval concerns were not confirmed: no bladder cystitis occurred despite years of exposure, cognitive function remained stable or improved, and misuse was rare (less than 0.01%). Serious adverse events were infrequent (less than 0.2% of sessions), occurring mainly during initial treatments. Mortality rates matched background rates in treatment resistant depression. Elderly patients showed similar tolerability but needed closer cardiovascular monitoring. Conclusion: Under proper clinical supervision, esketamine shows an acceptable safety profile. Most adverse effects are temporary and mild to moderate. Long term studies extending up to 6.5 years found no evidence of organ damage, cognitive decline, or meaningful abuse problems. For patients who have failed multiple treatments, esketamine provides an important alternative with manageable safety concerns.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
DIAGNOSTIC AND TREATMENT METHODS FOR URINARY TRACT INFECTIONS IN HEMATOLOGICAL PATIENTS
Research Objectives: To evaluate diagnostic and therapeutic methods for urinary tract infections (UTIs) in hematological patients, focusing on both conventional antimicrobial therapy and alternative treatment strategies in this immunocompromised population. Methods: Comprehensive literature review of diagnostic approaches including urine culture techniques, pathogen identification, and antimicrobial resistance patterns. Analysis of therapeutic strategies encompassing empirical and targeted antimicrobial therapy, alongside alternative modalities including cranberry supplementation, probiotics, urinary alkalinization, NSAIDs, and immunotherapy. Results: Hematological patients face elevated UTI risk (34.39% prevalence) with predominant pathogens including E. coli (19.99%) and Klebsiella spp. (5.12%), frequently exhibiting multidrug resistance. Rapid microbiological diagnosis with susceptibility testing is critical for preventing progression to urosepsis. Alternative therapies demonstrate prophylactic potential but cannot replace antimicrobial treatment in established infections. Conclusions: Effective UTI management in hematological patients requires rapid diagnostics, aggressive empirical therapy guided by local resistance patterns, and prompt de-escalation following susceptibility results. Alternative approaches serve valuable adjunctive roles but must not delay definitive antimicrobial therapy. Multidisciplinary collaboration and continuous protocol adaptation based on evolving resistance patterns optimize outcomes in this vulnerable population.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessDIAGNOSTIC AND TREATMENT METHODS FOR URINARY TRACT INFECTIONS IN HEMATOLOGICAL PATIENTS
Research Objectives: To evaluate diagnostic and therapeutic methods for urinary tract infections (UTIs) in hematological patients, focusing on both conventional antimicrobial therapy and alternative treatment strategies in this immunocompromised population. Methods: Comprehensive literature review of diagnostic approaches including urine culture techniques, pathogen identification, and antimicrobial resistance patterns. Analysis of therapeutic strategies encompassing empirical and targeted antimicrobial therapy, alongside alternative modalities including cranberry supplementation, probiotics, urinary alkalinization, NSAIDs, and immunotherapy. Results: Hematological patients face elevated UTI risk (34.39% prevalence) with predominant pathogens including E. coli (19.99%) and Klebsiella spp. (5.12%), frequently exhibiting multidrug resistance. Rapid microbiological diagnosis with susceptibility testing is critical for preventing progression to urosepsis. Alternative therapies demonstrate prophylactic potential but cannot replace antimicrobial treatment in established infections. Conclusions: Effective UTI management in hematological patients requires rapid diagnostics, aggressive empirical therapy guided by local resistance patterns, and prompt de-escalation following susceptibility results. Alternative approaches serve valuable adjunctive roles but must not delay definitive antimicrobial therapy. Multidisciplinary collaboration and continuous protocol adaptation based on evolving resistance patterns optimize outcomes in this vulnerable population.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
COBENFY (XANOMELINE-TROSPIUM CHLORIDE) AS A BREAKTHROUGH IN SCHIZOPHRENIA TREATMENT: POTENTIAL IMPACT ON PATIENT QUALITY OF LIFE AND HEALTHCARE ECONOMICS
In September 2024 FDA approved Cobenfy - the first antipsychotic with a novel mechanism of action in over 30 years. Unlike conventional antipsychotics that block D2 dopamine receptors, Cobenfy acts through muscarinic M1 and M4 receptor agonism. This matters because the side effects of traditional antipsychotics - weight gain, metabolic disturbances, movement disorders - are the main reason why about half of patients stop taking their medications. And when they stop, relapses follow. The EMERGENT trials demonstrated that Cobenfy achieves comparable efficacy (effect size 0.61) while avoiding the metabolic and extrapyramidal problems that plague existing treatments. For patients with schizophrenia, who already face a 15-20 year reduction in life expectancy largely due to cardiovascular disease, a medication that doesn't worsen their metabolic profile could be genuinely life-changing. But beyond individual health the implications extend to families exhausted by relapse cycles, to healthcare systems burdened by preventable hospitalizations, and to communities that have struggled to integrate people whose treatment makes normal functioning nearly impossible. Of course long-term data are still needed - approval came after relatively short trials. But the potential here is significant: better tolerability could mean better adherence, fewer relapses, less hospitalization, and ultimately patients who can actually participate in their own lives.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessCOBENFY (XANOMELINE-TROSPIUM CHLORIDE) AS A BREAKTHROUGH IN SCHIZOPHRENIA TREATMENT: POTENTIAL IMPACT ON PATIENT QUALITY OF LIFE AND HEALTHCARE ECONOMICS
In September 2024 FDA approved Cobenfy - the first antipsychotic with a novel mechanism of action in over 30 years. Unlike conventional antipsychotics that block D2 dopamine receptors, Cobenfy acts through muscarinic M1 and M4 receptor agonism. This matters because the side effects of traditional antipsychotics - weight gain, metabolic disturbances, movement disorders - are the main reason why about half of patients stop taking their medications. And when they stop, relapses follow. The EMERGENT trials demonstrated that Cobenfy achieves comparable efficacy (effect size 0.61) while avoiding the metabolic and extrapyramidal problems that plague existing treatments. For patients with schizophrenia, who already face a 15-20 year reduction in life expectancy largely due to cardiovascular disease, a medication that doesn't worsen their metabolic profile could be genuinely life-changing. But beyond individual health the implications extend to families exhausted by relapse cycles, to healthcare systems burdened by preventable hospitalizations, and to communities that have struggled to integrate people whose treatment makes normal functioning nearly impossible. Of course long-term data are still needed - approval came after relatively short trials. But the potential here is significant: better tolerability could mean better adherence, fewer relapses, less hospitalization, and ultimately patients who can actually participate in their own lives.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
ANTIDEPRESSANT-ASSOCIATED SEXUAL DYSFUNCTION (AASD) – FROM PATHOPHYSIOLOGY TO CLINICAL MANAGEMENT: A LITERATURE REVIEW
Major Depressive Disorder (MDD) presents a global challenge, with pharmacotherapy based on SSRIs and SNRIs remaining the standard of care. Despite clinical efficacy, the tolerability of these agents is often limited by iatrogenic Antidepressant-Associated Sexual Dysfunction (AASD), a leading cause of therapeutic non-adherence and so-called "hidden non-compliance," resulting in disease relapse. This paper provides a comprehensive literature review aimed at updating knowledge on epidemiology, neurobiological mechanisms extending beyond the serotonin hypothesis, and modern management strategies for AASD, with particular emphasis on Post-SSRI Sexual Dysfunction (PSSD). Databases including PubMed, ScienceDirect, Cochrane Library, and Google Scholar were searched, focusing on studies utilizing validated psychometric tools (e.g., ASEX, PRSexDQ). The analysis reveals a significant disparity between spontaneously reported AASD rates (10–15%) and those detected via screening (70–80%). A risk hierarchy was confirmed: paroxetine and venlafaxine demonstrate the highest iatrogenic potential, attributed partly to nitric oxide synthase inhibition and dopaminergic suppression. Vortioxetine and bupropion are characterized by a neutral profile, offering a safe alternative. The review also confirms the growing clinical importance of PSSD as a persistent complication. AASD requires proactive monitoring in daily practice. Results support moving away from a "wait and see" strategy in favor of routine screening and early implementation of switching or augmentation strategies. Personalization of pharmacotherapy is crucial for maintaining patient adherence and ensuring long-term depression treatment efficacy.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessANTIDEPRESSANT-ASSOCIATED SEXUAL DYSFUNCTION (AASD) – FROM PATHOPHYSIOLOGY TO CLINICAL MANAGEMENT: A LITERATURE REVIEW
Major Depressive Disorder (MDD) presents a global challenge, with pharmacotherapy based on SSRIs and SNRIs remaining the standard of care. Despite clinical efficacy, the tolerability of these agents is often limited by iatrogenic Antidepressant-Associated Sexual Dysfunction (AASD), a leading cause of therapeutic non-adherence and so-called "hidden non-compliance," resulting in disease relapse. This paper provides a comprehensive literature review aimed at updating knowledge on epidemiology, neurobiological mechanisms extending beyond the serotonin hypothesis, and modern management strategies for AASD, with particular emphasis on Post-SSRI Sexual Dysfunction (PSSD). Databases including PubMed, ScienceDirect, Cochrane Library, and Google Scholar were searched, focusing on studies utilizing validated psychometric tools (e.g., ASEX, PRSexDQ). The analysis reveals a significant disparity between spontaneously reported AASD rates (10–15%) and those detected via screening (70–80%). A risk hierarchy was confirmed: paroxetine and venlafaxine demonstrate the highest iatrogenic potential, attributed partly to nitric oxide synthase inhibition and dopaminergic suppression. Vortioxetine and bupropion are characterized by a neutral profile, offering a safe alternative. The review also confirms the growing clinical importance of PSSD as a persistent complication. AASD requires proactive monitoring in daily practice. Results support moving away from a "wait and see" strategy in favor of routine screening and early implementation of switching or augmentation strategies. Personalization of pharmacotherapy is crucial for maintaining patient adherence and ensuring long-term depression treatment efficacy.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
THE IMPACT OF POLYCYSTIC OVARY SYNDROME ON MENTAL HEALTH AND BODY IMAGE IN WOMEN: A CLINICAL LITERATURE REVIEW
Polycystic ovary syndrome (PCOS) represents the most common endocrine disorder in women of reproductive age, affecting 6–20% of this population depending on diagnostic criteria applied. Beyond its metabolic and reproductive consequences, PCOS significantly impacts mental health, particularly depression, anxiety, and body image disturbance. This clinical literature review synthesizes evidence from clinical studies and observational research examining the psychological burden of PCOS. Evidence indicates that women with PCOS experience markedly elevated rates of depression (approximately 49%) and anxiety compared to healthy controls, with depression predominantly presenting as mild to moderate severity. Lifestyle factors, including lack of exercise (OR=7.5), psychological stress (OR=6.5), sleep disturbance, and high-fat diet, constitute significant modifiable risk factors for depression. Body image disturbance emerges as a critical mediating factor between PCOS symptoms and psychological distress, affecting quality of life and overall well-being. Body appreciation, in contrast to mere absence of dissatisfaction, constitutes a particularly important protective factor for mental health. Cognitive-behavioral therapy (CBT) and psychosocial interventions demonstrate substantial efficacy in reducing depression and anxiety symptoms. Routine mental health screening and implementation of evidence-based psychological interventions are essential components of comprehensive PCOS care. This review emphasizes the necessity of integrated, multidisciplinary approaches addressing both physical and psychological aspects of PCOS, with particular attention to lifestyle modification as a therapeutic strategy.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessTHE IMPACT OF POLYCYSTIC OVARY SYNDROME ON MENTAL HEALTH AND BODY IMAGE IN WOMEN: A CLINICAL LITERATURE REVIEW
Polycystic ovary syndrome (PCOS) represents the most common endocrine disorder in women of reproductive age, affecting 6–20% of this population depending on diagnostic criteria applied. Beyond its metabolic and reproductive consequences, PCOS significantly impacts mental health, particularly depression, anxiety, and body image disturbance. This clinical literature review synthesizes evidence from clinical studies and observational research examining the psychological burden of PCOS. Evidence indicates that women with PCOS experience markedly elevated rates of depression (approximately 49%) and anxiety compared to healthy controls, with depression predominantly presenting as mild to moderate severity. Lifestyle factors, including lack of exercise (OR=7.5), psychological stress (OR=6.5), sleep disturbance, and high-fat diet, constitute significant modifiable risk factors for depression. Body image disturbance emerges as a critical mediating factor between PCOS symptoms and psychological distress, affecting quality of life and overall well-being. Body appreciation, in contrast to mere absence of dissatisfaction, constitutes a particularly important protective factor for mental health. Cognitive-behavioral therapy (CBT) and psychosocial interventions demonstrate substantial efficacy in reducing depression and anxiety symptoms. Routine mental health screening and implementation of evidence-based psychological interventions are essential components of comprehensive PCOS care. This review emphasizes the necessity of integrated, multidisciplinary approaches addressing both physical and psychological aspects of PCOS, with particular attention to lifestyle modification as a therapeutic strategy.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
TIRZEPATIDE AND RETATRUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: CURRENT EVIDENCE AND FUTURE DIRECTIONS. A SYSTEMATIC REVIEW OF CURRENT LITERATURE
Background: The global prevalence of obesity and type 2 diabetes mellitus (T2DM) has achieved unprecedented levels, imposing substantial burdens on healthcare systems worldwide. Incretin-based pharmacotherapies have fundamentally transformed therapeutic approaches to these metabolic disorders over the past decade. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide additionally targets glucagon receptors. Both agents represent groundbreaking advances in metabolic pharmacotherapy. Objective: This comprehensive review synthesizes clinical evidence from trials conducted between 2014 and 2024, examining pharmacological mechanisms, therapeutic efficacy, safety characteristics, and prospective clinical applications of these novel multi-receptor agonists. Methods: We performed systematic literature searches across PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases. Selection criteria encompassed randomized controlled trials, systematic reviews, meta-analyses, and prospective cohort studies, adhering to PRISMA methodology throughout. Results: Phase 3 clinical trials showed superior efficacy of tirzepatide compared to existing pharmacotherapies, reaching body weight reductions of approximately 22.5% and hemoglobin A1c (HbA1c) reductions of up to 2.4 percentage points. Phase 2 trials of retatrutide revealed even more remarkable outcomes, with weight reductions approaching 24.2% over 48 weeks. Both medications exhibited favorable cardiovascular profiles, though gastrointestinal adverse events constitute the predominant tolerability concern. Conclusions: These pharmacological agents represent paradigm-shifting developments in obesity and diabetes management. Their therapeutic effectiveness approximates outcomes previously achievable only through surgical intervention, marking a transformative milestone for pharmacotherapy. Ongoing phase 3 trials will further elucidate their optimal positioning within clinical treatment algorithms.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessTIRZEPATIDE AND RETATRUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: CURRENT EVIDENCE AND FUTURE DIRECTIONS. A SYSTEMATIC REVIEW OF CURRENT LITERATURE
Background: The global prevalence of obesity and type 2 diabetes mellitus (T2DM) has achieved unprecedented levels, imposing substantial burdens on healthcare systems worldwide. Incretin-based pharmacotherapies have fundamentally transformed therapeutic approaches to these metabolic disorders over the past decade. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide additionally targets glucagon receptors. Both agents represent groundbreaking advances in metabolic pharmacotherapy. Objective: This comprehensive review synthesizes clinical evidence from trials conducted between 2014 and 2024, examining pharmacological mechanisms, therapeutic efficacy, safety characteristics, and prospective clinical applications of these novel multi-receptor agonists. Methods: We performed systematic literature searches across PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases. Selection criteria encompassed randomized controlled trials, systematic reviews, meta-analyses, and prospective cohort studies, adhering to PRISMA methodology throughout. Results: Phase 3 clinical trials showed superior efficacy of tirzepatide compared to existing pharmacotherapies, reaching body weight reductions of approximately 22.5% and hemoglobin A1c (HbA1c) reductions of up to 2.4 percentage points. Phase 2 trials of retatrutide revealed even more remarkable outcomes, with weight reductions approaching 24.2% over 48 weeks. Both medications exhibited favorable cardiovascular profiles, though gastrointestinal adverse events constitute the predominant tolerability concern. Conclusions: These pharmacological agents represent paradigm-shifting developments in obesity and diabetes management. Their therapeutic effectiveness approximates outcomes previously achievable only through surgical intervention, marking a transformative milestone for pharmacotherapy. Ongoing phase 3 trials will further elucidate their optimal positioning within clinical treatment algorithms.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
EFFECTS OF BLUE LIGHT EXPOSURE ON RAPID EYE MOVEMENT SLEEP DURATION AND MELATONIN LEVELS IN CHILDREN: A COMPREHENSIVE LITERATURE REVIEW
Blue light exposure from electronic devices has emerged as a significant environmental factor affecting children's sleep architecture and circadian physiology. This comprehensive literature review synthesizes empirical evidence from 2020-2025 examining the effects of blue light exposure on rapid eye movement (REM) sleep duration and melatonin levels in pediatric populations. A systematic search of PubMed, Web of Science, and related databases identified studies employing objective measurement methods, including polysomnography (PSG) and actigraphy validated against PSG, with melatonin measurement via salivary DLMO. The current evidence demonstrates that blue light exposure, particularly from electronic devices in the evening hours, significantly suppresses melatonin production in children even at very low illuminance levels (5-40 lux), producing melatonin suppression of 70-99% depending on light intensity and spectral composition. Blue light predominantly affects melatonin suppression and REM sleep through intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing melanopsin with peak sensitivity at approximately 480 nm. Studies indicate that evening blue light exposure reduces REM sleep duration, increases REM fragmentation with elevated microarousals, increases sleep onset latency, and impairs sleep efficiency in children. The magnitude of effects on REM sleep and melatonin suppression demonstrates circadian timing dependency, with exposure during 21:00-22:30 hours producing maximum sleep disruption. Evening screen use, particularly interactive forms, is associated with delayed sleep onset and reduced total sleep duration in children measured via objective actigraphy. Interventions restricting blue light exposure before bedtime through screen abstinence and blue light-blocking glasses show slight improvements in sleep timing and circadian phase advancement. This review concludes that evidence-based guidelines recommending screen restriction in the 1-2 hours before bedtime are justified based on documented physiological mechanisms and objective sleep disruption in children.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessEFFECTS OF BLUE LIGHT EXPOSURE ON RAPID EYE MOVEMENT SLEEP DURATION AND MELATONIN LEVELS IN CHILDREN: A COMPREHENSIVE LITERATURE REVIEW
Blue light exposure from electronic devices has emerged as a significant environmental factor affecting children's sleep architecture and circadian physiology. This comprehensive literature review synthesizes empirical evidence from 2020-2025 examining the effects of blue light exposure on rapid eye movement (REM) sleep duration and melatonin levels in pediatric populations. A systematic search of PubMed, Web of Science, and related databases identified studies employing objective measurement methods, including polysomnography (PSG) and actigraphy validated against PSG, with melatonin measurement via salivary DLMO. The current evidence demonstrates that blue light exposure, particularly from electronic devices in the evening hours, significantly suppresses melatonin production in children even at very low illuminance levels (5-40 lux), producing melatonin suppression of 70-99% depending on light intensity and spectral composition. Blue light predominantly affects melatonin suppression and REM sleep through intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing melanopsin with peak sensitivity at approximately 480 nm. Studies indicate that evening blue light exposure reduces REM sleep duration, increases REM fragmentation with elevated microarousals, increases sleep onset latency, and impairs sleep efficiency in children. The magnitude of effects on REM sleep and melatonin suppression demonstrates circadian timing dependency, with exposure during 21:00-22:30 hours producing maximum sleep disruption. Evening screen use, particularly interactive forms, is associated with delayed sleep onset and reduced total sleep duration in children measured via objective actigraphy. Interventions restricting blue light exposure before bedtime through screen abstinence and blue light-blocking glasses show slight improvements in sleep timing and circadian phase advancement. This review concludes that evidence-based guidelines recommending screen restriction in the 1-2 hours before bedtime are justified based on documented physiological mechanisms and objective sleep disruption in children.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
THE IMPACT OF PROTON PUMP INHIBITORS ON KIDNEY FAILURE: LITERATURE REVIEW
Proton pump inhibitors (PPIs) are among the world's most frequently prescribed medications for treating acid-related gastrointestinal disorders. Increasing evidence from the past decade has raised concerns about their potential adverse effects on kidney function. This review examines multiple dimensions of PPI-associated nephrotoxicity, including acute interstitial nephritis (AIN), acute kidney injury (AKI), chronic kidney disease (CKD), progression and end-stage renal disease (ESRD). Multiple observational studies and meta-analyses have demonstrated connections between PPI use and adverse renal outcomes. The underlying mechanisms remain incompletely understood. The evidence suggests that PPIs may contribute to kidney dysfunction through various pathways, including immune-mediated reactions, alterations in magnesium homeostasis, changes in renal blood flow, and potential effects on gut microbiome-derived uremic toxins. While some recent studies challenge the strength of these correlations, the weight of evidence indicates a need for more judicious PPI prescribing, particularly in patients with existing kidney disease or risk factors for renal dysfunction. This work provides healthcare professionals with an understanding of current evidence, proposed mechanisms, clinical implications, and recommendations for PPI use in the context of kidney health.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessTHE IMPACT OF PROTON PUMP INHIBITORS ON KIDNEY FAILURE: LITERATURE REVIEW
Proton pump inhibitors (PPIs) are among the world's most frequently prescribed medications for treating acid-related gastrointestinal disorders. Increasing evidence from the past decade has raised concerns about their potential adverse effects on kidney function. This review examines multiple dimensions of PPI-associated nephrotoxicity, including acute interstitial nephritis (AIN), acute kidney injury (AKI), chronic kidney disease (CKD), progression and end-stage renal disease (ESRD). Multiple observational studies and meta-analyses have demonstrated connections between PPI use and adverse renal outcomes. The underlying mechanisms remain incompletely understood. The evidence suggests that PPIs may contribute to kidney dysfunction through various pathways, including immune-mediated reactions, alterations in magnesium homeostasis, changes in renal blood flow, and potential effects on gut microbiome-derived uremic toxins. While some recent studies challenge the strength of these correlations, the weight of evidence indicates a need for more judicious PPI prescribing, particularly in patients with existing kidney disease or risk factors for renal dysfunction. This work provides healthcare professionals with an understanding of current evidence, proposed mechanisms, clinical implications, and recommendations for PPI use in the context of kidney health.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
KETAMINE IN PREHOSPITAL MANAGEMENT OF TRAUMATIC BRAIN INJURIES: FROM CONTROVERSY TO ROUTINE USE. A SYSTEMATIC REVIEW OF CURRENT LITERATURE
Research Objectives: To present the broadest available evidence regarding the safety and efficacy of ketamine in traumatic brain injury (TBI) and explain the evolution of clinical guidelines. This review aims to verify historical contraindications against current knowledge and demonstrate how ketamine's role has evolved from a contraindicated drug to a potentially beneficial therapeutic option in prehospital settings. Methods: Systematic analysis of clinical studies and systematic reviews examining ketamine's effects on cerebral hemodynamics, intracranial pressure (ICP), and cerebral perfusion pressure (CPP). Evaluation of ketamine's utility as an analgesic-sedative drug in prehospital TBI care, including assessment of safety profiles and clinical outcomes across civilian and military settings. Conclusions: Ketamine's effect on cerebral hemodynamics is at least neutral and often beneficial, contrary to historical concerns about increased ICP. The drug demonstrates high utility as a prehospital analgesic-sedative agent, providing effective pain control and sedation without compromising patient safety. Historical contraindications must be regularly re-verified in light of current evidence. Clinical guidelines have evolved significantly, reflecting growing recognition that proper ventilation control and hemodynamic monitoring eliminate previous safety concerns. Current evidence supports ketamine as a safe and potentially advantageous therapeutic option in prehospital TBI management, particularly for achieving rapid sequence intubation, maintaining hemodynamic stability, and preventing secondary brain injury in emergency settings.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessKETAMINE IN PREHOSPITAL MANAGEMENT OF TRAUMATIC BRAIN INJURIES: FROM CONTROVERSY TO ROUTINE USE. A SYSTEMATIC REVIEW OF CURRENT LITERATURE
Research Objectives: To present the broadest available evidence regarding the safety and efficacy of ketamine in traumatic brain injury (TBI) and explain the evolution of clinical guidelines. This review aims to verify historical contraindications against current knowledge and demonstrate how ketamine's role has evolved from a contraindicated drug to a potentially beneficial therapeutic option in prehospital settings. Methods: Systematic analysis of clinical studies and systematic reviews examining ketamine's effects on cerebral hemodynamics, intracranial pressure (ICP), and cerebral perfusion pressure (CPP). Evaluation of ketamine's utility as an analgesic-sedative drug in prehospital TBI care, including assessment of safety profiles and clinical outcomes across civilian and military settings. Conclusions: Ketamine's effect on cerebral hemodynamics is at least neutral and often beneficial, contrary to historical concerns about increased ICP. The drug demonstrates high utility as a prehospital analgesic-sedative agent, providing effective pain control and sedation without compromising patient safety. Historical contraindications must be regularly re-verified in light of current evidence. Clinical guidelines have evolved significantly, reflecting growing recognition that proper ventilation control and hemodynamic monitoring eliminate previous safety concerns. Current evidence supports ketamine as a safe and potentially advantageous therapeutic option in prehospital TBI management, particularly for achieving rapid sequence intubation, maintaining hemodynamic stability, and preventing secondary brain injury in emergency settings.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
CURRENT ADVANCES IN LIPOPROTEIN(A) MANAGEMENT: CLINICAL SIGNIFICANCE AND EMERGING THERAPIES
Background: Lipoprotein(a) [Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Despite its clinical importance, Lp(a) remains largely unaffected by traditional lipid-lowering therapies, contributing to significant residual cardiovascular risk. Aim: This review aims to synthesize current knowledge regarding the clinical significance of elevated lipoprotein(a) levels and to explore the landscape of emerging therapeutic strategies designed to specifically address this challenging cardiovascular risk factor. Materials and Methods: An extensive synthesis of the current literature, prioritizing comprehensive review articles and meta-analyses published within the last five years, was conducted using multiple electronic databases (PubMed, Scopus, Google Scholar). Results: Epidemiological data indicate that 20–30% of the global population has elevated Lp(a) levels (>30–50 mg/dL). While lifestyle and statins show negligible effects on Lp(a) concentration, novel nucleic acid-based therapies - specifically antisense oligonucleotides (pelacarsen) and small interfering RNAs (olpasiran, lepodisiran, zerlasiran) have demonstrated the ability to reduce Lp(a) levels by 70% to over 95%. Furthermore, oral small-molecule inhibitors like muvalaplin offer promising alternatives by disrupting the assembly of the Lp(a) particle. Conclusion: The emergence of targeted RNA-based and small-molecule therapies represents a paradigm shift in cardiovascular prevention. As phase 3 clinical trials progress, these interventions may provide the first definitive means of mitigating the residual risk associated with elevated Lp(a).
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessCURRENT ADVANCES IN LIPOPROTEIN(A) MANAGEMENT: CLINICAL SIGNIFICANCE AND EMERGING THERAPIES
Background: Lipoprotein(a) [Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Despite its clinical importance, Lp(a) remains largely unaffected by traditional lipid-lowering therapies, contributing to significant residual cardiovascular risk. Aim: This review aims to synthesize current knowledge regarding the clinical significance of elevated lipoprotein(a) levels and to explore the landscape of emerging therapeutic strategies designed to specifically address this challenging cardiovascular risk factor. Materials and Methods: An extensive synthesis of the current literature, prioritizing comprehensive review articles and meta-analyses published within the last five years, was conducted using multiple electronic databases (PubMed, Scopus, Google Scholar). Results: Epidemiological data indicate that 20–30% of the global population has elevated Lp(a) levels (>30–50 mg/dL). While lifestyle and statins show negligible effects on Lp(a) concentration, novel nucleic acid-based therapies - specifically antisense oligonucleotides (pelacarsen) and small interfering RNAs (olpasiran, lepodisiran, zerlasiran) have demonstrated the ability to reduce Lp(a) levels by 70% to over 95%. Furthermore, oral small-molecule inhibitors like muvalaplin offer promising alternatives by disrupting the assembly of the Lp(a) particle. Conclusion: The emergence of targeted RNA-based and small-molecule therapies represents a paradigm shift in cardiovascular prevention. As phase 3 clinical trials progress, these interventions may provide the first definitive means of mitigating the residual risk associated with elevated Lp(a).